Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer

被引:8
作者
Ault, Kevin [1 ]
Reisinger, Keith [2 ]
机构
[1] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30303 USA
[2] Primary Phys Res Inc, Pittsburgh, PA USA
关键词
cervical cancer; human papillomavirus; screening; vaccination; cervical screening;
D O I
10.1016/S1201-9712(07)60018-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Cervical cancer remains an important health problem even in countries with effective cervical screening programs. HPV vaccines offer great potential for primary prevention of cervical cancer and other HPV-retated diseases. Perspectives: Eventual implementation of an HPV vaccination program raises several key issues, Cervical screening including universal vs. targeted vaccinations, the age and gender of vaccine recipients, the acceptability of this vaccine to health care providers, adolescents, and parents, and the effect of this vaccine on cervical cancer screening. These issues were explored among symposium attendees during an interactive question-and-answer session using computerized voting pads. Conclusions: Preventative HPV vaccination programs should ideally be executed universally in both women and men with an emphasis on children and adolescents prior to their first sexual experience. Parent education on HPV disease and vaccine efficacy and safety will be critical to the acceptability of HPV vaccination for their children. HPV vaccination will not eliminate the need for Pap screening. Further research wilt be needed to develop rational and cost-effective cervical surveillance programs for women protected by HPV vaccines. (c) 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:S26 / S28
页数:3
相关论文
共 14 条
[1]  
[Anonymous], CURR STAT DEV PROPH
[2]   Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination [J].
Bottiger, M ;
Forsgren, M .
VACCINE, 1997, 15 (14) :1538-1544
[3]   Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes [J].
Brabin, L ;
Roberts, SA ;
Farzaneh, F ;
Kitchener, HC .
VACCINE, 2006, 24 (16) :3087-3094
[4]  
Davis Kristin, 2004, J Low Genit Tract Dis, V8, P188, DOI 10.1097/00128360-200407000-00005
[5]  
*DEP HLTH HUM SERV, GEN HPV INF FACT SHE
[6]   Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control [J].
Franco, EL ;
Harper, DA .
VACCINE, 2005, 23 (17-18) :2388-2394
[7]   The health and economic burden of genital warts in a set of private health plans in the United States [J].
Insinga, RP ;
Dasbach, EJ ;
Myers, ER .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (11) :1397-1403
[8]   Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico [J].
Lazcano-Ponce, E ;
Rivera, L ;
Arillo-Santillán, E ;
Salmerón, J ;
Hernández-Avila, M ;
Muñoz, N .
ARCHIVES OF MEDICAL RESEARCH, 2001, 32 (03) :243-247
[9]  
MARGOLIS H, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P720
[10]  
Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1